Dawson James analyst Jason Kolbert maintained a Buy rating on Cytosorbents (CTSO – Research Report) on November 9 and set a price target of $16.00. The company's shares closed last Tuesday at $4.03. According to TipRanks.com, Kolbert is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytosorbents with a $12.75 average price target, representing a 195.8% upside.
https://www.tipranks.com/news/blurbs/dawson-james-sticks-to-their-buy-rating-for-cytosorbents-ctso?utm_source=advfn.com&utm_medium=referral